| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 52 | 2024 | 860 | 5.980 |
Why?
|
| Melanoma | 28 | 2019 | 943 | 2.920 |
Why?
|
| Nevus, Pigmented | 9 | 2014 | 32 | 1.500 |
Why?
|
| Dysplastic Nevus Syndrome | 7 | 2017 | 21 | 1.470 |
Why?
|
| Nevus | 9 | 2016 | 35 | 1.420 |
Why?
|
| Histiocytoma, Benign Fibrous | 3 | 2024 | 12 | 1.420 |
Why?
|
| Mycosis Fungoides | 4 | 2016 | 14 | 1.360 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2024 | 71 | 1.130 |
Why?
|
| Drug Eruptions | 2 | 2021 | 32 | 1.130 |
Why?
|
| Diagnosis, Differential | 23 | 2024 | 1902 | 1.060 |
Why?
|
| Immunohistochemistry | 24 | 2019 | 1703 | 0.890 |
Why?
|
| Chickenpox | 1 | 2024 | 20 | 0.890 |
Why?
|
| Hemorrhoids | 1 | 2024 | 10 | 0.880 |
Why?
|
| Herpes Zoster | 1 | 2024 | 23 | 0.880 |
Why?
|
| Skin | 6 | 2019 | 521 | 0.820 |
Why?
|
| Skin Diseases | 4 | 2022 | 129 | 0.800 |
Why?
|
| Staining and Labeling | 3 | 2021 | 184 | 0.800 |
Why?
|
| Paget Disease, Extramammary | 1 | 2021 | 3 | 0.740 |
Why?
|
| Colitis, Ulcerative | 1 | 2024 | 208 | 0.730 |
Why?
|
| Adenine | 1 | 2021 | 104 | 0.720 |
Why?
|
| Artifacts | 1 | 2021 | 109 | 0.680 |
Why?
|
| Piperidines | 1 | 2021 | 208 | 0.670 |
Why?
|
| Melanoma-Specific Antigens | 4 | 2014 | 9 | 0.630 |
Why?
|
| Biomarkers, Tumor | 13 | 2022 | 1534 | 0.630 |
Why?
|
| Sezary Syndrome | 2 | 2011 | 12 | 0.600 |
Why?
|
| Mucinosis, Follicular | 2 | 2021 | 2 | 0.580 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 177 | 0.580 |
Why?
|
| Humans | 85 | 2024 | 125358 | 0.520 |
Why?
|
| Melanocytes | 7 | 2022 | 48 | 0.510 |
Why?
|
| Dermatofibrosarcoma | 2 | 2008 | 17 | 0.500 |
Why?
|
| Pathology | 2 | 2015 | 41 | 0.500 |
Why?
|
| Dermatology | 1 | 2015 | 34 | 0.470 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2014 | 25 | 0.470 |
Why?
|
| Cryotherapy | 1 | 2014 | 22 | 0.460 |
Why?
|
| Steroids | 1 | 2015 | 202 | 0.460 |
Why?
|
| Truth Disclosure | 1 | 2015 | 102 | 0.450 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 62 | 0.450 |
Why?
|
| Male | 42 | 2024 | 61561 | 0.430 |
Why?
|
| Neoplasms, Second Primary | 3 | 2013 | 146 | 0.420 |
Why?
|
| Diagnostic Errors | 2 | 2015 | 334 | 0.420 |
Why?
|
| Aged | 23 | 2024 | 19727 | 0.410 |
Why?
|
| Margins of Excision | 3 | 2017 | 51 | 0.410 |
Why?
|
| Eyelid Neoplasms | 2 | 2016 | 43 | 0.410 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2012 | 4 | 0.410 |
Why?
|
| Dermatomycoses | 1 | 2012 | 18 | 0.400 |
Why?
|
| Neoplasm Proteins | 3 | 2008 | 681 | 0.400 |
Why?
|
| Leuprolide | 1 | 2012 | 22 | 0.400 |
Why?
|
| Ethics, Medical | 1 | 2015 | 396 | 0.400 |
Why?
|
| Immunocompromised Host | 2 | 2013 | 294 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1157 | 0.380 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 257 | 0.350 |
Why?
|
| Antigens, CD | 3 | 2008 | 430 | 0.350 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2009 | 65 | 0.340 |
Why?
|
| Adult | 25 | 2024 | 29540 | 0.340 |
Why?
|
| Acanthoma | 2 | 2022 | 5 | 0.340 |
Why?
|
| Receptors, Leptin | 2 | 2010 | 40 | 0.320 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2011 | 223 | 0.320 |
Why?
|
| Cell Adhesion Molecules | 2 | 2008 | 231 | 0.310 |
Why?
|
| Cryosurgery | 1 | 2009 | 47 | 0.310 |
Why?
|
| Nose Neoplasms | 1 | 2008 | 32 | 0.300 |
Why?
|
| Nevus, Blue | 1 | 2008 | 2 | 0.290 |
Why?
|
| Giant Cell Tumors | 1 | 2008 | 5 | 0.290 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 71 | 0.290 |
Why?
|
| Arm | 1 | 2008 | 82 | 0.290 |
Why?
|
| Nitrogen | 3 | 2014 | 145 | 0.280 |
Why?
|
| Middle Aged | 29 | 2024 | 26765 | 0.280 |
Why?
|
| Receptors, Thyrotropin | 1 | 2006 | 10 | 0.270 |
Why?
|
| Scalp | 2 | 2024 | 57 | 0.270 |
Why?
|
| Thyrotropin | 1 | 2006 | 56 | 0.270 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 6560 | 0.270 |
Why?
|
| Female | 34 | 2024 | 66815 | 0.260 |
Why?
|
| Conjunctival Neoplasms | 1 | 2006 | 22 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 625 | 0.250 |
Why?
|
| Actins | 1 | 2008 | 345 | 0.250 |
Why?
|
| Specimen Handling | 1 | 2006 | 142 | 0.240 |
Why?
|
| Lymphocyte Subsets | 1 | 2005 | 38 | 0.240 |
Why?
|
| Carcinosarcoma | 2 | 2015 | 11 | 0.230 |
Why?
|
| Hamartoma Syndrome, Multiple | 2 | 2016 | 20 | 0.230 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 247 | 0.230 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2005 | 121 | 0.230 |
Why?
|
| Hemangiosarcoma | 2 | 2016 | 41 | 0.220 |
Why?
|
| MART-1 Antigen | 3 | 2022 | 14 | 0.220 |
Why?
|
| Fibrosis | 2 | 2019 | 442 | 0.220 |
Why?
|
| Herpesvirus 3, Human | 1 | 2024 | 26 | 0.220 |
Why?
|
| Giant Cells | 1 | 2004 | 34 | 0.220 |
Why?
|
| Heel | 1 | 2023 | 9 | 0.220 |
Why?
|
| Fibroma | 1 | 2004 | 30 | 0.210 |
Why?
|
| Immunization, Secondary | 1 | 2024 | 104 | 0.210 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2014 | 5 | 0.210 |
Why?
|
| Stevens-Johnson Syndrome | 2 | 2017 | 13 | 0.200 |
Why?
|
| Neck | 1 | 2004 | 135 | 0.200 |
Why?
|
| Keratosis, Actinic | 1 | 2022 | 12 | 0.200 |
Why?
|
| Skin Abnormalities | 1 | 2022 | 33 | 0.200 |
Why?
|
| Piperazines | 3 | 2008 | 242 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2017 | 669 | 0.180 |
Why?
|
| Genital Neoplasms, Male | 1 | 2021 | 12 | 0.180 |
Why?
|
| Vulvar Neoplasms | 1 | 2021 | 18 | 0.180 |
Why?
|
| Dermatitis | 2 | 2019 | 26 | 0.180 |
Why?
|
| Keratoacanthoma | 2 | 2018 | 5 | 0.170 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2013 | 15 | 0.170 |
Why?
|
| Pyrimidines | 3 | 2008 | 377 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 137 | 0.170 |
Why?
|
| Lymphatic Metastasis | 4 | 2009 | 418 | 0.160 |
Why?
|
| Panniculitis | 1 | 2019 | 19 | 0.160 |
Why?
|
| Radiodermatitis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Biopsy | 8 | 2019 | 1244 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 138 | 0.160 |
Why?
|
| Esomeprazole | 1 | 2019 | 32 | 0.160 |
Why?
|
| Granuloma | 1 | 2019 | 68 | 0.160 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 38 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 62 | 0.160 |
Why?
|
| Necrobiosis Lipoidica | 1 | 2018 | 1 | 0.150 |
Why?
|
| Granuloma Annulare | 1 | 2018 | 2 | 0.150 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 10 | 0.150 |
Why?
|
| Antineoplastic Agents | 5 | 2008 | 1714 | 0.150 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 2 | 2008 | 5 | 0.150 |
Why?
|
| Leptin | 2 | 2010 | 213 | 0.140 |
Why?
|
| Linear IgA Bullous Dermatosis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Genome, Human | 2 | 2015 | 1292 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 5171 | 0.140 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2017 | 8 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 544 | 0.140 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2008 | 16 | 0.140 |
Why?
|
| Lipocalin-2 | 1 | 2017 | 30 | 0.140 |
Why?
|
| Parotid Neoplasms | 1 | 2016 | 16 | 0.130 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 1275 | 0.130 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2007 | 100 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1720 | 0.130 |
Why?
|
| Superinfection | 1 | 2016 | 6 | 0.130 |
Why?
|
| Enterobacter | 1 | 2016 | 14 | 0.130 |
Why?
|
| 12E7 Antigen | 2 | 2008 | 2 | 0.130 |
Why?
|
| Hair Follicle | 2 | 2007 | 34 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 290 | 0.130 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 121 | 0.130 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2016 | 54 | 0.130 |
Why?
|
| Antigens, CD34 | 2 | 2008 | 106 | 0.120 |
Why?
|
| beta Catenin | 1 | 2017 | 214 | 0.120 |
Why?
|
| Administration, Cutaneous | 1 | 2015 | 66 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 2 | 2012 | 503 | 0.120 |
Why?
|
| Vancomycin | 1 | 2017 | 217 | 0.120 |
Why?
|
| Eyelids | 1 | 2016 | 119 | 0.120 |
Why?
|
| Eye Infections, Bacterial | 1 | 2016 | 92 | 0.120 |
Why?
|
| Hydroa Vacciniforme | 1 | 2014 | 3 | 0.120 |
Why?
|
| Leishmania guyanensis | 1 | 2014 | 3 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 114 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2012 | 1982 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 4 | 2007 | 259 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 781 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2017 | 340 | 0.110 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2014 | 48 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2012 | 2373 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 2430 | 0.110 |
Why?
|
| Hidrocystoma | 1 | 2013 | 4 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2009 | 1026 | 0.110 |
Why?
|
| Ultraviolet Rays | 1 | 2014 | 204 | 0.110 |
Why?
|
| Cheek | 1 | 2013 | 27 | 0.110 |
Why?
|
| Nocardia | 1 | 2013 | 8 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2008 | 384 | 0.110 |
Why?
|
| Facial Neoplasms | 1 | 2013 | 19 | 0.110 |
Why?
|
| Nocardia Infections | 1 | 2013 | 14 | 0.110 |
Why?
|
| Dapsone | 3 | 2021 | 6 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 653 | 0.100 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2013 | 23 | 0.100 |
Why?
|
| Membrane Proteins | 3 | 2019 | 1538 | 0.100 |
Why?
|
| Snake Venoms | 1 | 2012 | 3 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2012 | 260 | 0.100 |
Why?
|
| Disease Progression | 5 | 2018 | 2084 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 81 | 0.100 |
Why?
|
| Signal Transduction | 4 | 2010 | 4595 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 1592 | 0.100 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 142 | 0.100 |
Why?
|
| Biopsy, Needle | 2 | 2011 | 228 | 0.100 |
Why?
|
| Inflammation | 1 | 2019 | 1445 | 0.100 |
Why?
|
| Abscess | 1 | 2013 | 139 | 0.100 |
Why?
|
| Epidermis | 1 | 2012 | 63 | 0.090 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 5 | 0.090 |
Why?
|
| Azathioprine | 1 | 2011 | 54 | 0.090 |
Why?
|
| Mutation | 2 | 2015 | 5904 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 256 | 0.090 |
Why?
|
| Celiac Disease | 1 | 2011 | 67 | 0.090 |
Why?
|
| Prednisone | 1 | 2011 | 278 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 1756 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2006 | 106 | 0.080 |
Why?
|
| Neurothekeoma | 1 | 2009 | 1 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2010 | 210 | 0.080 |
Why?
|
| S100 Proteins | 1 | 2009 | 46 | 0.080 |
Why?
|
| Clusterin | 1 | 2009 | 11 | 0.080 |
Why?
|
| Lymph Nodes | 2 | 2008 | 378 | 0.080 |
Why?
|
| Methotrexate | 1 | 2011 | 336 | 0.080 |
Why?
|
| Neoplasm Metastasis | 5 | 2012 | 706 | 0.080 |
Why?
|
| Epithelioid Cells | 1 | 2008 | 11 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 12 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 2182 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2009 | 327 | 0.070 |
Why?
|
| Prognosis | 4 | 2011 | 4686 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2019 | 16363 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 240 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2010 | 1111 | 0.070 |
Why?
|
| Quinolones | 1 | 2008 | 54 | 0.070 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2011 | 293 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 532 | 0.070 |
Why?
|
| Myosins | 1 | 2008 | 47 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 145 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 2799 | 0.070 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2007 | 19 | 0.070 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2007 | 3 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2008 | 231 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2007 | 2061 | 0.070 |
Why?
|
| Tissue Array Analysis | 4 | 2008 | 137 | 0.070 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2007 | 37 | 0.070 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2007 | 13 | 0.070 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2007 | 4 | 0.070 |
Why?
|
| Epidermal Cyst | 1 | 2007 | 19 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 374 | 0.070 |
Why?
|
| Genes, erbB-2 | 1 | 2007 | 37 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 645 | 0.070 |
Why?
|
| Sunlight | 1 | 2006 | 24 | 0.070 |
Why?
|
| Adenoma | 1 | 2008 | 128 | 0.070 |
Why?
|
| Transcription Factors | 3 | 2007 | 2603 | 0.070 |
Why?
|
| Cadherins | 1 | 2008 | 172 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2006 | 35 | 0.070 |
Why?
|
| Pyridines | 1 | 2008 | 235 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2006 | 680 | 0.070 |
Why?
|
| Galectin 3 | 1 | 2006 | 36 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 326 | 0.060 |
Why?
|
| Vasculitis | 1 | 2006 | 49 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2007 | 236 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 2008 | 440 | 0.060 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2006 | 8 | 0.060 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 48 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2006 | 247 | 0.060 |
Why?
|
| Diphtheria Toxin | 1 | 2005 | 12 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 278 | 0.060 |
Why?
|
| Lymphoma, Follicular | 1 | 2005 | 26 | 0.060 |
Why?
|
| Carcinoma | 1 | 2008 | 290 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 493 | 0.060 |
Why?
|
| Hypothyroidism | 1 | 2006 | 92 | 0.060 |
Why?
|
| Skin Aging | 1 | 2005 | 14 | 0.060 |
Why?
|
| Alopecia | 1 | 2005 | 39 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2005 | 29 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 664 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2007 | 339 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2007 | 772 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2005 | 244 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 214 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2006 | 408 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 143 | 0.060 |
Why?
|
| Young Adult | 2 | 2016 | 9058 | 0.060 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 2004 | 10 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 381 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2007 | 472 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 284 | 0.060 |
Why?
|
| Eosinophils | 1 | 2005 | 120 | 0.060 |
Why?
|
| Omalizumab | 1 | 2024 | 33 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2003 | 9 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2019 | 12287 | 0.050 |
Why?
|
| Imatinib Mesylate | 3 | 2008 | 45 | 0.050 |
Why?
|
| Cell Survival | 1 | 2006 | 821 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2007 | 801 | 0.050 |
Why?
|
| Benzamides | 3 | 2008 | 110 | 0.050 |
Why?
|
| SOXE Transcription Factors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 802 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 1033 | 0.050 |
Why?
|
| Nose | 1 | 2022 | 94 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2006 | 503 | 0.050 |
Why?
|
| Pregnancy | 1 | 2014 | 7226 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1909 | 0.050 |
Why?
|
| Leg | 1 | 2022 | 155 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 561 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1272 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1104 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 1025 | 0.040 |
Why?
|
| Retinoids | 1 | 2021 | 34 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2006 | 3044 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 2520 | 0.040 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2019 | 23 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 36 | 0.040 |
Why?
|
| Debridement | 1 | 2019 | 89 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2019 | 118 | 0.040 |
Why?
|
| Necrosis | 1 | 2019 | 209 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2018 | 910 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2004 | 1034 | 0.040 |
Why?
|
| Elastic Tissue | 1 | 2018 | 19 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 138 | 0.040 |
Why?
|
| Elastin | 1 | 2018 | 31 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 100 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 114 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4409 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 1097 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 880 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 292 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 175 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2019 | 3431 | 0.030 |
Why?
|
| Wound Healing | 1 | 2019 | 460 | 0.030 |
Why?
|
| DNA Primers | 2 | 2008 | 657 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2006 | 296 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 264 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1294 | 0.030 |
Why?
|
| Cuba | 1 | 2014 | 6 | 0.030 |
Why?
|
| Panama | 1 | 2014 | 12 | 0.030 |
Why?
|
| Antiprotozoal Agents | 1 | 2014 | 37 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2014 | 90 | 0.030 |
Why?
|
| Adolescent | 5 | 2010 | 19423 | 0.030 |
Why?
|
| Travel | 1 | 2014 | 115 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 217 | 0.030 |
Why?
|
| Child | 5 | 2014 | 24606 | 0.030 |
Why?
|
| Hand | 1 | 2013 | 100 | 0.020 |
Why?
|
| Hyperpigmentation | 1 | 2011 | 12 | 0.020 |
Why?
|
| Mice | 2 | 2019 | 17750 | 0.020 |
Why?
|
| Teaching Rounds | 1 | 2011 | 28 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 3420 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4423 | 0.020 |
Why?
|
| Animals | 3 | 2019 | 34318 | 0.020 |
Why?
|
| S100 Calcium Binding Protein A6 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1240 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2013 | 346 | 0.020 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2009 | 3 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 461 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2011 | 191 | 0.020 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2009 | 13 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6311 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 60 | 0.020 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2009 | 46 | 0.020 |
Why?
|
| Back | 1 | 2008 | 9 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1692 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 283 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1634 | 0.020 |
Why?
|
| Niacinamide | 1 | 2008 | 23 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2008 | 53 | 0.020 |
Why?
|
| Thorax | 1 | 2008 | 73 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 49 | 0.020 |
Why?
|
| Extremities | 1 | 2008 | 83 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 93 | 0.020 |
Why?
|
| Melanins | 1 | 2007 | 18 | 0.020 |
Why?
|
| Abdomen | 1 | 2008 | 127 | 0.020 |
Why?
|
| Merkel Cells | 1 | 2007 | 4 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2007 | 13 | 0.020 |
Why?
|
| Ankle | 1 | 2007 | 29 | 0.020 |
Why?
|
| Hair Diseases | 1 | 2007 | 14 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2007 | 18 | 0.020 |
Why?
|
| Chromogranins | 1 | 2007 | 26 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2007 | 31 | 0.020 |
Why?
|
| Axilla | 1 | 2007 | 39 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 145 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 306 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2007 | 134 | 0.020 |
Why?
|
| Thoracic Wall | 1 | 2007 | 39 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2006 | 12 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2006 | 19 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 57 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1065 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 165 | 0.020 |
Why?
|
| Claudin-1 | 1 | 2005 | 20 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 634 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 133 | 0.020 |
Why?
|
| Procollagen | 1 | 2005 | 13 | 0.020 |
Why?
|
| United States | 2 | 2014 | 10908 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2005 | 102 | 0.010 |
Why?
|
| Low-Level Light Therapy | 1 | 2005 | 15 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 101 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 10296 | 0.010 |
Why?
|
| Phototherapy | 1 | 2005 | 35 | 0.010 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2005 | 72 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2005 | 357 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 472 | 0.010 |
Why?
|
| COP9 Signalosome Complex | 1 | 2004 | 11 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1172 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 404 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2004 | 61 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 196 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 3111 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 1315 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 1362 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2004 | 145 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 2909 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 586 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 509 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 772 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 491 | 0.010 |
Why?
|
| Disease Management | 1 | 2006 | 530 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 1189 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 1284 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 2813 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1269 | 0.010 |
Why?
|
| Texas | 1 | 2005 | 3581 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 3106 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 4270 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 12601 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 14145 | 0.010 |
Why?
|